Trial intelligence / Profile preview

AK104 plus neoadjuvant chemotherapy and radiotherapy for stage III–IV cervical cancer

ChiCTR2400083092Phase 2Not yet recruiting

Sponsor: Nantong Cancer Hospital
Start: Apr 2024
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label trial of cadonilimab in Cervical Cancer (CC) (2 arms), sponsored by Nantong Cancer Hospital. Primary endpoints: Progression-free survival (PFS), Overall survival at 2 years (2-year OS rate) and 1 more. Planned start Apr 2024; status: not yet recruiting.

Drugs

cadonilimab

Conditions

Cervical Cancer (CC)

Beyond the preview

Go deeper on ChiCTR2400083092.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400083092.